The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients
Birdwell K, Grady B, Choi L, Xu H, Bian A, Denny J, Jiang M, Vranic G, Basford M, Cowan J, Richardson D, Robinson M, Ikizler T, Ritchie M, Stein C, Haas D. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenetics And Genomics 2012, 22: 32-42. PMID: 22108237, PMCID: PMC3237759, DOI: 10.1097/fpc.0b013e32834e1641.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Body WeightCytochrome P-450 CYP3ADatabases, Nucleic AcidDose-Response Relationship, DrugDrug MonitoringElectronic Health RecordsFemaleGenetic Association StudiesGenotypeHemoglobinsHumansImmunosuppressive AgentsKidney TransplantationLinkage DisequilibriumMaleMiddle AgedPolymorphism, Single NucleotidePregnane X ReceptorReceptors, SteroidTacrolimusConceptsTacrolimus dose requirementsKidney transplant recipientsDose requirementsElectronic medical recordsBlood concentrationsTransplant recipientsMedical recordsCYP3A5 rs776746Electronic medical record dataInterindividual pharmacokinetic variabilityTacrolimus blood concentrationsNarrow therapeutic indexDNA biobanksMedical record dataTherapeutic drug monitoringDrug-metabolizing enzymesKidney transplantationClinical factorsPrimary outcomeImmunosuppressive drugsPharmacokinetic variabilityTacrolimus clearanceClinical covariatesPharmacogenomic predictorsTherapeutic index